Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Clinigen Appoints New CFO | Contract Pharma
Breaking News, Promotions & Moves

Clinigen Appoints New CFO

Nick Keher joins from Royal Bank of Canada (RBC) where he was a managing director and head of RBC’s European Healthcare equity research team

Clinigen Group has appointed Nick Keher as Group chief financial officer effective March 19, 2019. He will replace Martin Abell, who has resigned effective March 31, 2019.

Nick joins from Royal Bank of Canada (RBC) where he was a managing director and head of RBC’s European Healthcare equity research team. He has covered the European healthcare space for over eight years at both RBC and Investec.

Nick started his career at Lloyd’s Pharmacy, registering as a pharmacist before joining GlaxoSmithKline (GSK). At GSK Nick worked within the Group’s R&D, UK Commercial Operations and Global Manufacturing & Supply Strategy finance teams where he trained as an accountant. 

 
Peter Allen, chairman of Clinigen, said, “On behalf of the Board and everyone at Clinigen, I would like to thank Martin for his substantial contribution over the last three and a half years. During which time Clinigen has undergone a period of rapid change and development including the acquisitions and integration of Idis, Link, Quantum and CSM, plus a number of products. We wish him every success for the future.”

Shaun Chilton, Group chief executive officer of Clinigen, said, “Nick brings considerable pharmacy and pharmaceutical experience as well as financial expertise, both as an accountant and from working in the financial markets. He has a deep knowledge and insight of our business through his research and analysis of Clinigen since its IPO in 2012. He will be a key addition to the executive management team.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters